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Background
Valproic acid (VLA), carbamazepine (CBZ) and most of
the newest anti-seizure agents have nowadays an estab-
lished use in psychiatric pharmacotherapy, not only in
bipolar affective disorder but also,off-license though in a
variety of disorders. The effects of the anti-seizure medica-
tions on B12, folate and homocysteine levels have been a
topic of research. The related 1-carbon metabolism has
been implicated in mental disorders. So, taking into
account all the above we reviewed the literature about the
potential benefit of monitoring B12 and folate levels on
patients receiving anti-seizure medication, especially VLA
or CBZ.
Materials and methods
We reviewed the guidelines as given by official Institutes
in UK and USA, namely NICE (National Institute for Clin-
ical Excellence) and APA (American Psychiatric Associa-
tion). Articles related to the subject were also reviewed
after relevant search via the Medline [1,2]. As far as the
involvement of impaired 1-carbon metabolism in the
neurochemistry of affective and anxiety disorders, it
appears the evidence from both clinical (involving trials
albeit of a small scale) and basic research, is suggestive of
a degree of involvement in their pathophysiology
(stronger evidence exists for folate). We also found evi-
dence suggestive of adverse effects of the anti-seizure med-
ications on B12, folate and homocysteine levels-none of
which is routinely monitored (or advised so by guide-
lines) in patients receiving such medication for mental
disorders.
Results
As far as the involvement of impaired 1-carbon metabo-
lism in the neurochemistry of affective and anxiety disor-
ders, it appears the evidence from both clinical (involving
trials albeit of a small scale) and basic research, is sugges-
tive of a degree of involvement in their pathophysiology
(stronger evidence exists for folate). We also found evi-
dence suggestive of adverse effects of the anti-seizure med-
ications on B12, folate and homocysteine levels-none of
which is routinely monitored (or advised so by guide-
lines) in patients receiving such medication for mental
disorders.
Conclusions
The findings both from clinical studies and basic science
research suggest a role of the an impaired 1-carbon metab-
olism in the pathophysiology of cognitive decline (includ-
ing Alzheimer's disease) and mood disorders, especially
depression with implications regarding treatment. There
are also weaker indications of involvement in anxiety dis-
orders. In brief, B12, folate and homocysteine are
involved in very important central nervous system func-
tions: Folate metabolism is linked to biopterin-dependent
neurotransmitter synthesis and biogenic amine methyla-
tion with B12 involved as a co-factor. Homocysteine and
its metabolite homocysteic acid, may have a direct neuro-
toxic effect, involving NMDA receptors. Homocysteine
levels are increased in B12 and folate deficiency. It appears
that the long term use of anti-seizure drugs, especially car-
bamazepine and valproate has unfavorable effects on B12
and folate levels. Taking all the above into consideration,
we find it reasonable to suggest that a six monthly or
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yearly monitoring of B12, folate and possibly homo-
cysteine levels would be a cost effective intervention with
advantageous effects in this group of patients.
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